Therapeutic Enoxaparin is Required for Your Patient
You should immediately increase the enoxaparin dose from prophylactic 40 mg once daily to therapeutic 1 mg/kg subcutaneously every 12 hours. This patient has multiple high-risk thrombotic conditions—antiphospholipid syndrome (APS) with recurrent DVT, atrial fibrillation, and recent NSTEMI/STEMI—all requiring full therapeutic anticoagulation, not prophylaxis 1, 2.
Why Prophylactic Dosing is Inadequate
Your current 40 mg daily dose is designed for VTE prophylaxis in hospitalized medical patients 3. This patient has active thrombotic disease requiring treatment-level anticoagulation:
- Recurrent DVT with APS: Requires therapeutic anticoagulation indefinitely 4
- Recent NSTEMI/STEMI: Guidelines specify enoxaparin 1 mg/kg every 12 hours for ACS 1, 2
- Atrial fibrillation: Adds stroke risk requiring therapeutic anticoagulation 4
The 2025 ACC/AHA ACS guidelines explicitly state therapeutic enoxaparin dosing as "1 mg/kg subcutaneous every 12 h" for initial therapy 1, 2. Prophylactic dosing leaves this patient dramatically under-anticoagulated.
Correct Enoxaparin Dosing
Dose: 1 mg/kg subcutaneously every 12 hours 1, 2
Dose adjustments:
- If creatinine clearance <30 mL/min: reduce to 1 mg/kg once daily 1, 2
- Continue until warfarin achieves therapeutic INR for at least 48 hours 4
Managing the Warfarin Transition
When warfarin can be started:
- Begin warfarin immediately while continuing therapeutic enoxaparin 4
- Overlap for 4-5 days minimum until INR is therapeutic for 48 consecutive hours 4
- Target INR 2.5 (range 2.0-3.0) for the DVT and atrial fibrillation 4
- Consider higher intensity (INR 2.5-3.5 or even 3.0-4.0) given APS with recurrent thrombosis—this is controversial but some evidence supports higher targets in high-risk APS 5
Critical warning about APS: The FDA label and recent evidence strongly suggest warfarin (not DOACs) for APS patients, especially those with triple-positive antibodies or arterial thrombosis 4, 5, 6. DOACs have shown treatment failure in high-risk APS 6.
Antiplatelet Management Post-NSTEMI/STEMI
Current recommendations:
- Aspirin 81 mg daily should continue indefinitely 1, 7
- P2Y12 inhibitor (clopidogrel 75 mg daily preferred over prasugrel/ticagrelor when combined with anticoagulation) for 12 months post-ACS 1, 7
- Triple therapy duration: Aspirin + clopidogrel + anticoagulation should be limited to minimize bleeding risk 8, 9
When warfarin is therapeutic:
- Continue aspirin 75-100 mg daily (lower dose reduces bleeding) 9
- Continue clopidogrel 75 mg daily for up to 12 months post-NSTEMI 7
- Target INR 2.0-2.5 (lower end) when combining with dual antiplatelet therapy to reduce bleeding 7, 8
After 12 months post-ACS, consider dropping one antiplatelet agent (typically aspirin) and continuing warfarin + clopidogrel, or warfarin alone, depending on bleeding risk 8, 9.
Key Pitfalls to Avoid
- Do not use prophylactic enoxaparin dosing for active thrombotic disease—this is treatment failure waiting to happen
- Do not switch between enoxaparin and UFH during therapy—increased bleeding risk 10
- Do not use DOACs in this patient with APS and recurrent thrombosis—warfarin is superior 5, 6, 11
- Do not stop enoxaparin prematurely—maintain overlap until INR therapeutic ≥48 hours 4
- Monitor platelet count on enoxaparin (risk of heparin-induced thrombocytopenia, though lower than UFH)
If PCI is Needed
If the patient requires PCI while on enoxaparin 1, 2:
- If last dose <8 hours ago: No additional enoxaparin needed
- If last dose 8-12 hours ago: Give 0.3 mg/kg IV bolus
- If only 1 dose given: Give 0.3 mg/kg IV bolus
This prevents both under- and over-anticoagulation during the procedure 12.